Thrivent Financial for Lutherans Has $108 Million Holdings in Gilead Sciences, Inc. $GILD

Thrivent Financial for Lutherans boosted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 20.5% during the 3rd quarter, HoldingsChannel reports. The fund owned 972,988 shares of the biopharmaceutical company’s stock after buying an additional 165,304 shares during the quarter. Thrivent Financial for Lutherans’ holdings in Gilead Sciences were worth $108,001,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of GILD. GoalVest Advisory LLC lifted its holdings in Gilead Sciences by 7,566.7% during the second quarter. GoalVest Advisory LLC now owns 230 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 227 shares in the last quarter. Corundum Trust Company INC acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth $26,000. Harbor Asset Planning Inc. bought a new stake in shares of Gilead Sciences during the 2nd quarter worth $27,000. Howard Hughes Medical Institute bought a new stake in Gilead Sciences during the 2nd quarter worth $30,000. Finally, Putney Financial Group LLC boosted its stake in shares of Gilead Sciences by 53.4% in the 2nd quarter. Putney Financial Group LLC now owns 270 shares of the biopharmaceutical company’s stock valued at $30,000 after purchasing an additional 94 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences News Summary

Here are the key news stories impacting Gilead Sciences this week:

• Positive Sentiment: Multiple sell‑side firms raised targets and reiterated bullish ratings (Wolfe Research to $155/outperform; TD Cowen to $145/buy), reinforcing buy-side momentum and implied upside from current levels. Read More. Read More.
• Positive Sentiment: Broader analyst upgrades/positive notes from Citi, Truist, BMO and UBS add to consensus bullishness, supporting demand and higher valuation multiples. Read More.
• Positive Sentiment: Clinical/regulatory wins for Trodelvy (added to NCCN guidelines; TNBC approval/win coverage) strengthen Gilead’s oncology growth story and revenue optionality beyond antivirals. Read More. Read More.
• Positive Sentiment: Coverage pieces noting that GILD has outperformed the market and is attracting analyst attention can draw momentum and ETF/quant flows into the stock. Read More.
• Neutral Sentiment: Notes on GILD’s presence in Nasdaq/healthcare ETF lineups and elevated investor attention increase volume and liquidity but are not clear directional catalysts by themselves. Read More.
• Negative Sentiment: Insider selling: CEO Daniel Patrick O’Day sold 10,000 shares (~$1.4M) at ~$139.89 (filed on Form 4). While modest relative to his remaining holding and potentially routine, insider sales can be interpreted negatively by some investors. Read More.

Gilead Sciences Stock Up 1.7%

NASDAQ:GILD opened at $141.95 on Friday. The company has a current ratio of 1.45, a quick ratio of 1.31 and a debt-to-equity ratio of 1.03. Gilead Sciences, Inc. has a twelve month low of $93.37 and a twelve month high of $142.20. The company’s 50 day moving average is $125.36 and its two-hundred day moving average is $119.67. The company has a market cap of $176.11 billion, a PE ratio of 22.01, a P/E/G ratio of 0.73 and a beta of 0.33.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.47 earnings per share for the quarter, beating the consensus estimate of $2.16 by $0.31. Gilead Sciences had a return on equity of 51.86% and a net margin of 27.88%.The firm had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.42 billion. During the same quarter in the previous year, the business earned $2.02 EPS. Gilead Sciences’s revenue for the quarter was up 3.0% compared to the same quarter last year. Analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently commented on the stock. Mizuho increased their target price on shares of Gilead Sciences from $131.00 to $140.00 and gave the company an “outperform” rating in a report on Friday, November 21st. Sanford C. Bernstein set a $135.00 price target on shares of Gilead Sciences and gave the company an “outperform” rating in a report on Monday, December 29th. Royal Bank Of Canada boosted their target price on shares of Gilead Sciences from $100.00 to $103.00 and gave the company a “sector perform” rating in a report on Tuesday, January 20th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Gilead Sciences in a report on Thursday, January 22nd. Finally, TD Cowen boosted their price target on Gilead Sciences from $125.00 to $145.00 and gave the company a “buy” rating in a report on Thursday. One research analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $136.73.

Insider Transactions at Gilead Sciences

In related news, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction dated Wednesday, January 28th. The stock was sold at an average price of $139.89, for a total transaction of $1,398,900.00. Following the transaction, the chief executive officer owned 556,698 shares of the company’s stock, valued at approximately $77,876,483.22. This represents a 1.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Andrew D. Dickinson sold 3,000 shares of the business’s stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $124.31, for a total transaction of $372,930.00. Following the transaction, the chief financial officer owned 150,503 shares of the company’s stock, valued at $18,709,027.93. This trade represents a 1.95% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 257,397 shares of company stock worth $33,385,512 in the last 90 days. Insiders own 0.27% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.